Debio 1454M

Debio 1454M is a preclinical, narrow-spectrum microbiome-remodeling drug discovery program originating from Debiopharm and licensed to Takeda for further development as a microbiome-targeting therapeutic for gastrointestinal disorders, particularly inflammatory bowel disease. It comprises small-molecule agents designed to selectively target and suppress specific intestinal pathobiont bacterial species implicated in dysbiosis-driven gut inflammation, while sparing beneficial commensal bacteria to preserve overall microbiota balance.[1][5][8][9][10] Under the Debio 1454M program, Takeda is responsible for screening and optimizing compounds to generate clinical candidates that can modulate the gut microbiome as a novel approach to treating chronic inflammatory GI diseases such as Crohn’s disease and ulcerative colitis.[1][5][7][8][10]